Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.
Adding two targeted drugs to a liver cancer procedure reduces immune suppression and improves survival outcomes in early patient data.
TACE induces PDGFC+ TAM-mediated vascular-immune niche dysfunction via pericyte-to-fibroblast transition; low-dose bevacizumab + atezolizumab corrects hypoxia, reduces immunosuppression, and improves clinical outcomes after TACE in retrospective cohort analysis. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- translational (snRNA-seq + multi-cohort validation + retrospective clinical analysis)
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- J Hepatol
Why it surfaced
High-impact Journal of Hepatology publication; mechanistic snRNA-seq discovery directly translatable to an actionable combination therapy strategy for HCC (major unmet need); multi-cohort validation adds translational credibility. Immediately relevant to ongoing clinical trial design in HCC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.